Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

NCT02277093 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped FDA issued a clinical hold as pacritinib had increased side effects

Conditions

Colorectal Cancer

Interventions

DRUG: Pacritinib

Sponsor

Washington University School of Medicine

Collaborators

[object Object]